Skip to content

Fúlvio Rieli Mendes

Universidade Federal do ABC

2 papers in the library · 65 citations · publishing 2018-2022

Papers

Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research

Addiction Neuroscience June 22, 2022 Fúlvio Rieli Mendes, Cristiane Dos Santos Costa, Victor Distefano Wiltenburg et al. 55 citations

Substance use disorder (SUD) affects millions globally, often impairing brain reward circuits and personal life. Treatments face challenges like limited availability and poor patient retention. A non-systematic review of studies published through December 2021 examined classic (LSD, DMT, psilocybin, mescaline) and non-classic (ibogaine, ketamine, MDMA, salvinorin A, THC) psychedelics for SUD. Results are inconclusive for LSD, DMT, mescaline, MDMA, and salvinorin A. Moderate evidence supports psilocybin and ketamine for alcohol use disorder, ketamine for opiate and alcohol withdrawal, and THC preparations for reducing withdrawal in cannabis and possibly opioid use disorder. Psychedelics appear more effective as adjunct therapy. More research is needed.

Pre-clinical interaction of ayahuasca, a brew used in spiritual movements, with morphine and propofol

Brazilian Journal of Pharmaceutical Sciences June 7, 2018 Júlia Movilla Pires, Fúlvio Rieli Mendes, Ana Paula Salum Pires et al. 10 citations

Ayahuasca, a psychoactive beverage used in religious rituals, contains dimethyltryptamine and harmala alkaloids that activate serotonergic pathways. In mice, ayahuasca alone reduced pain in writhing and formalin tests and boosted morphine's analgesic effect on the hot plate test. It intensified propofol's depressant effect in the rotarod test but shortened propofol-induced sleeping time. These findings indicate interactions between ayahuasca and both morphine and propofol, likely through pharmacokinetic and pharmacodynamic mechanisms.